Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00096668
Recruitment Status : Completed
First Posted : November 15, 2004
Last Update Posted : June 4, 2009
Information provided by:
Achieve Life Sciences

Brief Summary:
This is an open label study where each patient will receive TOCOSOL(R) Paclitaxel 120mg/m2 every week for first line treatment of metastatic breast cancer. Patients will be followed to determine the efficacy of treatment (as measured by objective response rate), and the safety associated with weekly administration of TOCOSOL Paclitaxel.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: TOCOSOL(R) Paclitaxel Phase 2

Detailed Description:
This is an open label, non-randomized Phase 2 study of weekly administration of TOCOSOL Paclitaxel at a dose level, 120mg/m2, known to be tolerated based on Phase 2a studies of this investigational agent in patients with other histological diagnoses. This study is a fixed sample size design with no planned early stopping decision. The goals of the study include the determination of the safety of TOCOSOL Paclitaxel, and the objective response rate, defined by RECIST criteria as complete responses plus partial responses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 47 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(R) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) as Initial Treatment of Patients With Metastatic Breast Cancer
Study Start Date : October 2004
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: TOCOSOL Paclitaxel
TOCOSOL Paclitaxel administered weekly at 120mg/mm2
Drug: TOCOSOL(R) Paclitaxel

Primary Outcome Measures :
  1. Tolerability [ Time Frame: After all patients complete treatment ]

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: After alll patients complete treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patient with histologic diagnosis of breast carcinoma
  • Stage IV (M1) disease
  • No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer
  • Adult (18 years of age or older) patients
  • Adequate hematologic function (ANC >=1500 cells/mm3 and platelets >100,000/mm3
  • Serum creatinine <=2.0 mg/dL
  • Total bilirubin <=1.5 mg/dL
  • AST/SGOT and ALT/SGPT <=3 times the upper limit of institutional normal values
  • PT and PTT within institutional normal range
  • ECOG performance status of 0-2
  • At least one unidimensionally measurable lesion as defined by RECIST criteria assessable by radiographic evaluation
  • A signed IRB/Ethics Committee approved Informed Consent
  • Life expectancy of at least 12 weeks
  • Fully recovered from any previous surgery
  • A negative pregnancy test prior to study entry if premenopausal
  • Agree not to take Vitamin E supplementation while receiving study medication

Exclusion Criteria:

  • Any prior taxane-containing chemotherapy including Taxol or Taxotere
  • Patients who are pregnant or lactating
  • Peripheral neuropathy NCI-CTC grade 2 or greater
  • Wide-field radiation, hormonal therapy or trastuzumab within 4 weeks of first dose of study drug; cytotoxic chemotherapy within 6 months of first dose of study drug
  • Treatment with an investigational agent within 4 weeks of first dose of study drug
  • Patients with a history of carcinomas of primary sites which can not be distinguished histologically from metastatic breast carcinoma
  • Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of metastatic breast carcinoma
  • Brain metastases
  • Active bowel obstruction
  • Active, serious infection or other serious medical problems (other than metastatic breast cancer) likely to impair completion of the study protocol
  • Concurrent therapy with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 or CYP3A4
  • Concurrent therapy with warfarin or other coumarin derivatives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00096668

Layout table for location information
Russian Federation
Arkhangelsk Regional Oncology Center
Arkhangelsk, Russian Federation, 163045
Moscow Oncology Clinical Hospital #62
Krasnogorskiy Region, Russian Federation, 143423
Blokhin Russian Oncology Center
Moscow, Russian Federation, 115478
Semashko Central Clinical Hospital of the Ministry of Transport
Moscow, Russian Federation, 129128
St Petersburg Oncology Center
St Petersburg, Russian Federation, 197022
Petrov Research Institute of Oncology
St Petersburg, Russian Federation, 197758
Voronezh Regional Clinical Oncology Center
Voronezh, Russian Federation, 3394000
Sponsors and Collaborators
Achieve Life Sciences

Layout table for additonal information
Responsible Party: Monica Krieger, VP Regulatory Affairs, OncoGenex Pharmaceuticals Identifier: NCT00096668    
Other Study ID Numbers: SON-8184-1074
First Posted: November 15, 2004    Key Record Dates
Last Update Posted: June 4, 2009
Last Verified: June 2009
Keywords provided by Achieve Life Sciences:
Breast cancer
TOCOSOL Paclitaxel
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action